Research Analysts Issue Forecasts for BEAM Q1 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Beam Therapeutics in a note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst M. Foroohar expects that the company will earn ($1.26) per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. Leerink Partnrs also issued estimates for Beam Therapeutics’ FY2026 earnings at ($5.09) EPS.

A number of other research analysts also recently weighed in on the stock. Leerink Partners raised shares of Beam Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the company from $27.00 to $39.00 in a research report on Wednesday, November 6th. Sanford C. Bernstein raised shares of Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 7th. Guggenheim reissued a “buy” rating and set a $78.00 target price on shares of Beam Therapeutics in a research report on Thursday. Wedbush reissued an “outperform” rating and set a $57.00 target price on shares of Beam Therapeutics in a research report on Monday, January 13th. Finally, Royal Bank of Canada raised their price objective on shares of Beam Therapeutics from $24.00 to $26.00 and gave the stock a “sector perform” rating in a report on Wednesday. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Beam Therapeutics has a consensus rating of “Buy” and an average price target of $50.90.

Beam Therapeutics Stock Down 2.8 %

Beam Therapeutics stock opened at $27.11 on Thursday. Beam Therapeutics has a twelve month low of $20.84 and a twelve month high of $45.79. The firm has a 50 day moving average price of $27.22 and a 200-day moving average price of $25.91. The company has a market capitalization of $2.24 billion, a P/E ratio of -15.40 and a beta of 1.92.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.16. Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The business had revenue of $30.00 million during the quarter, compared to the consensus estimate of $16.47 million. During the same period in the prior year, the firm posted $1.73 EPS. The firm’s quarterly revenue was down 90.5% compared to the same quarter last year.

Insiders Place Their Bets

In other news, insider Christine Bellon sold 1,241 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total transaction of $30,627.88. Following the sale, the insider now owns 102,968 shares in the company, valued at approximately $2,541,250.24. This trade represents a 1.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO John M. Evans sold 30,000 shares of the firm’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $26.75, for a total transaction of $802,500.00. Following the sale, the chief executive officer now owns 908,659 shares in the company, valued at approximately $24,306,628.25. This trade represents a 3.20 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.20% of the company’s stock.

Institutional Trading of Beam Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Beam Therapeutics during the 4th quarter valued at $330,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Beam Therapeutics by 6.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 629,492 shares of the company’s stock valued at $15,423,000 after purchasing an additional 36,226 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Beam Therapeutics by 11.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,957,611 shares of the company’s stock valued at $98,149,000 after purchasing an additional 404,782 shares during the last quarter. Bellevue Group AG grew its holdings in shares of Beam Therapeutics by 7.1% during the 3rd quarter. Bellevue Group AG now owns 1,518,121 shares of the company’s stock valued at $37,194,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Beam Therapeutics by 4.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,807,683 shares of the company’s stock valued at $44,297,000 after purchasing an additional 78,102 shares during the last quarter. Hedge funds and other institutional investors own 99.68% of the company’s stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.